Initial results from the Phase III CheckMate -227 study have demonstrated that the combination of nivolumab plus ipilimumab can significantly extend PFS in those with previously untreated advanced NSCLC whose tumours have high tumour mutation burden (TMB).
To mark World Health Day we spoke with Ivo Abraham from the University of Arizona (AZ, USA) about the role that biosimilars play in expanding access to cancer treatments, particularly in regards to the biosimilar filgrastim-sndz.
In this interview find out what advancements have been made in the field of biosimilars and how they are helping improve access to cancer medicines.
A novel treatment strategy could overcome drug resistance in testicular cancer, find out exclusive details in this interview with study leader Janet Shipley from the ICR (London, UK).
In this joint interview we delve deeper into the news story to find out both the clinician’s and patient’s perspective on the recent recommendation of ixazomib for NHS distribution.
John Ellwood discusses the treatment he underwent following his diagnosis with myeloma.
To mark International Women’s Day we recently spoke with Victoria Sanz Moreno from Kings College London (UK) to find out what inspired her to get into cancer research.
To mark Rare Disease Day we recently spoke with Jonathan Wadsley (Weston Park Hospital, Sheffield, UK) about recent advancements in care for medullary thyroid cancer.
Right now, doctors can’t tell whether women with DCIS will go on to develop breast cancer. This means that, unfortunately, some women with DCIS undergo unnecessary treatment. Find out how Jelle and his team are looking to change this.
In this interview Roshaine Wijayatunga (Senior Editor: Oncology) speaks with David Jayne about colorectal surgery in regards to the development, application and evaluation of new surgical technologies.